loading
SeaStar Medical Holding Corp stock is currently priced at $0.3714, with a 24-hour trading volume of 687.81K. It has seen a +1.42% increased in the last 24 hours and a -22.66% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.3731 pivot point. If it approaches the $0.3582 support level, significant changes may occur.
Previous Close:
$0.3662
Open:
$0.37
24h Volume:
687.81K
Market Cap:
$28.01M
Revenue:
-
Net Income/Loss:
$-26.23M
P/E Ratio:
-0.4067
EPS:
-0.9133
Net Cash Flow:
$-10.29M
1W Performance:
-0.51%
1M Performance:
-22.66%
6M Performance:
-27.02%
1Y Performance:
-28.58%
1D Range:
Value
$0.3651
$0.386
52W Range:
Value
$0.162
$1.7169

SeaStar Medical Holding Corp Stock (ICU) Company Profile

Name
Name
SeaStar Medical Holding Corp
Name
Phone
844 427 8100
Name
Address
3513 Brighton Boulevard, Suite 410, Denver
Name
Employee
8
Name
Twitter
Name
Next Earnings Date
2024-06-04
Name
Latest SEC Filings
Name
ICU's Discussions on Twitter

SeaStar Medical Holding Corp Stock (ICU) Financials Data

SeaStar Medical Holding Corp (ICU) Net Income 2024

ICU net income (TTM) was -$26.23 million for the quarter ending December 31, 2023, a -115.19% decrease year-over-year.
loading

SeaStar Medical Holding Corp (ICU) Cash Flow 2024

ICU recorded a free cash flow (TTM) of -$10.29 million for the quarter ending December 31, 2023, a -31.96% decrease year-over-year.
loading

SeaStar Medical Holding Corp (ICU) Earnings per Share 2024

ICU earnings per share (TTM) was -$1.2274 for the quarter ending December 31, 2023, a -27.87% decline year-over-year.
loading
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
$75.07
price up icon 0.79%
$148.85
price down icon 3.50%
$28.20
price up icon 0.75%
$148.43
price down icon 1.07%
$371.02
price up icon 2.45%
$100.60
price up icon 1.87%
Cap:     |  Volume (24h):